miR-21 in the Extracellular Vesicles (EVs) of Cerebrospinal Fluid (CSF): A Platform for Glioblastoma Biomarker Development
Open accessThe DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Abstract
Glioblastoma cells secrete extra-cellular vesicles (EVs) containing microRNAs (miRNAs). Analysis of these EV miRNAs in the bio-fluids of afflicted patients represents a potential platform for biomarker development. However, the analytic algorithm for quantitative assessment of EV miRNA remains under-developed. Here, we demonstrate that the reference transcripts commonly used for quantitative PCR (including GAPDH, 18S rRNA, and hsa-miR-103) were unreliable for assessing EV miRNA. In this context, we quantitated EV miRNA in absolute terms and normalized this value to the input EV number. Using this method, we examined the abundance of miR-21, a highly over-expressed miRNA in glioblastomas, in EVs. In a panel of glioblastoma cell lines, the cellular levels of miR-21 correlated with EV miR-21 levels (p<0.05), suggesting that glioblastoma cells actively secrete EVs containing miR-21. Consistent with this hypothesis, the CSF EV miR-21 levels of glioblastoma patients (n=13) were, on average, ten-fold higher than levels in EVs isolated from the CSF of non-oncologic patients (n=13, p<0.001). Notably, none of the glioblastoma CSF harbored EV miR-21 level below 0.25 copies per EV in this cohort. Using this cut-off value, we were able to prospectively distinguish CSF derived from glioblastoma and non-oncologic patients in an independent cohort of twenty-nine patients (Sensitivity=87%; Specificity=93%; AUC=0.91, p<0.01). Our results suggest that CSF EV miRNA analysis of miR-21 may serve as a platform for glioblastoma biomarker development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
RETRACTED: MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer
Taylor, D. D., & Gercel-Taylor, C. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.04.033 · Cited by 2,288
RetractedPregnancy-Associated Exosomes and Their Modulation of T Cell Signaling
Taylor, D. D., Akyol, S., & Gercel-Taylor, C. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.3.1534 · Cited by 297 · cited 1×
“Since non-neoplastic cells secrete EVs [18–20] and they outnumber neoplastic cells by several orders of magnitude in a patient [21], tumor-specific EVs remain a rarity in clinical samples [22].”
BackgroundRetractedAnalysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Extracellular vesicles: Exosomes, microvesicles, and friends
Raposo, G., & Stoorvogel, W. (2013) · Journal of Cell Biology · doi:10.1083/jcb.201211138 · Cited by 8,099 · cited 1×
“EVs isolated from biofluids can encompass exosomes, microvesicles, retrovirus-like particles (RLPs) and apoptotic bodies [66,67].”
BackgroundVerhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575 · cited 1×
“of glioblastoma subtypes [79], whether subtyping can be”
BackgroundReceiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine
Zweig, M. H., & Campbell, G. (1993) · Clinical Chemistry · doi:10.1093/clinchem/39.4.561 · Cited by 6,569
Isolation and Characterization of Exosomes from Cell Culture Supernatants and Biological Fluids
Théry, C., Amigorena, S., Raposo, G., & Clayton, A. (2006) · Current Protocols in Cell Biology · doi:10.1002/0471143030.cb0322s30 · Cited by 5,766
Skog, J., Würdinger, T., van Rijn, S., Meijer, D. H., Gainche, L., Curry, W. T., Carter, B. S., Krichevsky, A. M., & Breakefield, X. O. (2008) · Nature Cell Biology · doi:10.1038/ncb1800 · Cited by 5,001
Self-citationBustin, S. (2000) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0250169 · Cited by 3,872
Mutation of the mouse klotho gene leads to a syndrome resembling ageing
Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837
Cited by
Doyle, L., & Wang, M. (2019) · Cells · doi:10.3390/cells8070727 · Cited by 3,236
Exosomes in cancer development, metastasis, and immunity
Zhang, L., & Yu, D. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.04.004 · Cited by 870
Exosome mediated communication within the tumor microenvironment
Milane, L., Singh, A., Mattheolabakis, G., Suresh, M., & Amiji, M. M. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.06.029 · Cited by 742
MicroRNAome genome: A treasure for cancer diagnosis and therapy
Berindan‐Neagoe, I., Monroig, P. D. C., Pasculli, B., & Calin, G. A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21244 · Cited by 522
Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review
Singh, N., Miner, A., Hennis, L., & Mittal, S. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.79 · Cited by 398
Extracellular Vesicle Quantification and Characterization: Common Methods and Emerging Approaches
Hartjes, T. A., Mytnyk, S., Jenster, G. W., van Steijn, V., & van Royen, M. E. (2019) · Bioengineering · doi:10.3390/bioengineering6010007 · Cited by 342
Exosomal noncoding RNAs in Glioma: biological functions and potential clinical applications
Cheng, J., Meng, J., Zhu, L., & Peng, Y. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01189-3 · Cited by 319
EVmiRNA: a database of miRNA profiling in extracellular vesicles
Liu, T., Zhang, Q., Zhang, J., Li, C., Miao, Y.-R., Lei, Q., Li, Q., & Guo, A.-Y. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky985 · Cited by 314
Momen-Heravi, F., Saha, B., Kodys, K., Catalano, D., Satishchandran, A., & Szabo, G. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0623-9 · Cited by 307
Shi, R., Wang, P.-Y., Li, X.-Y., Chen, J.-X., Li, Y., Zhang, X.-Z., Zhang, C.-G., Jiang, T., Li, W.-B., Ding, W., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4699 · Cited by 285
An, T., Qin, S., Xu, Y., Tang, Y., Huang, Y., Situ, B., Inal, J. M., & Zheng, L. (2015) · Journal of Extracellular Vesicles · doi:10.3402/jev.v4.27522 · Cited by 282
Extracellular vesicles and intercellular communication within the nervous system
Zappulli, V., Friis, K. P., Fitzpatrick, Z., Maguire, C. A., & Breakefield, X. O. (2016) · Journal of Clinical Investigation · doi:10.1172/jci81134 · Cited by 255
Self-citationExtracellular vesicles as circulating cancer biomarkers: opportunities and challenges
Lane, R. E., Korbie, D., Hill, M. M., & Trau, M. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-018-0192-7 · Cited by 245
“For example, studies of glioblastoma multiforme have indicated that tumour-EV in the cerebrospinal fluid contain elevated levels of miR21 relative to healthy controls, and that EV-miR21 levels reflect tumour burden [64, 65].”
BackgroundMethodGlioblastoma: exosome and microRNA as novel diagnosis biomarkers
Saadatpour, L., Fadaee, E., Fadaei, S., Nassiri Mansour, R., Mohammadi, M., Mousavi, S. M., Goodarzi, M., Verdi, J., & Mirzaei, H. (2016) · Cancer Gene Therapy · doi:10.1038/cgt.2016.48 · Cited by 244
Silantyev, A., Falzone, L., Libra, M., Gurina, O., Kardashova, K., Nikolouzakis, T., Nosyrev, A., Sutton, C., Mitsias, P., & Tsatsakis, A. (2019) · Cells · doi:10.3390/cells8080863 · Cited by 227
Extracellular Vesicles and Their Roles in Cancer Progression
Chang, W.-H., Cerione, R. A., & Antonyak, M. A. (2021) · Methods in Molecular Biology · doi:10.1007/978-1-0716-0759-6_10 · Cited by 224
The Liquid Biopsy Consortium: Challenges and opportunities for early cancer detection and monitoring
Batool, S. M., Yekula, A., Khanna, P., Hsia, T., Gamblin, A. S., Ekanayake, E., Escobedo, A. K., You, D. G., Castro, C. M., Im, H., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101198 · Cited by 213
Self-citationFigueroa, J. M., Skog, J., Akers, J., Li, H., Komotar, R., Jensen, R., Ringel, F., Yang, I., Kalkanis, S., Thompson, R., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox085 · Cited by 204
Self-citationFunctions and clinical significance of circular RNAs in glioma
Sun, J., Li, B., Shu, C., Ma, Q., & Wang, J. (2020) · Molecular Cancer · doi:10.1186/s12943-019-1121-0 · Cited by 196
Atomic force microscopy analysis of extracellular vesicles
Parisse, P., Rago, I., Ulloa Severino, L., Perissinotto, F., Ambrosetti, E., Paoletti, P., Ricci, M., Beltrami, A. P., Cesselli, D., & Casalis, L. (2017) · European Biophysics Journal · doi:10.1007/s00249-017-1252-4 · Cited by 163
MicroRNAs as potential biomarkers for the diagnosis of glioma: A systematic review and meta‐analysis
Zhou, Q., Liu, J., Quan, J., Liu, W., Tan, H., & Li, W. (2018) · Cancer Science · doi:10.1111/cas.13714 · Cited by 160
Sources and Functions of Extracellular Small RNAs in Human Circulation
Fritz, J. V., Heintz-Buschart, A., Ghosal, A., Wampach, L., Etheridge, A., Galas, D., & Wilmes, P. (2016) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071715-050711 · Cited by 121
Extracellular Vesicles in Brain Tumors and Neurodegenerative Diseases
Ciregia, F., Urbani, A., & Palmisano, G. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00276 · Cited by 110
“…within subpopulations of EVs which were fractionated using differential centrifugation. miR-21, togheter with other GBM-pertinent miRNAs, are highly enriched in EVs derived from CSF of GBM patients while they are not detectable in EV depleted CSF, confirming previous results (Akers et al., 2013).”
ResultDifferent sourced extracellular vesicles and their potential applications in clinical treatments
Bahmani, L., & Ullah, M. (2022) · Cells · doi:10.3390/cells11131989 · Cited by 83
“Cerebrospinal fluid (CSF) collection for selective isolation of N-EVs is quite challenging because of the invasive nature of the procedure and the small size of the resultant samples [194,195].”
BackgroundThe role of MiRNA-21 in gliomas: Hope for a novel therapeutic intervention?
Aloizou, A.-M., Pateraki, G., Siokas, V., Mentis, A.-F. A., Liampas, I., Lazopoulos, G., Kovatsi, L., Mitsias, P. D., Bogdanos, D. P., Paterakis, K., et al. (2020) · Toxicology Reports · doi:10.1016/j.toxrep.2020.11.001 · Cited by 69
miR-137: A Novel Therapeutic Target for Human Glioma
Wang, Y., Chen, R., Zhou, X., Guo, R., Yin, J., Li, Y., & Ma, G. (2020) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2020.06.028 · Cited by 40
Circulating microRNAs as emerging non-invasive biomarkers for gliomas
Santangelo, A., Tamanini, A., Cabrini, G., & Dechecchi, M. C. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.06.15 · Cited by 36
“Notably, levels of exosome miR-21 in CSF allow to discriminate GBM IV from non-oncologic patients (26) and circulating serum levels probably reflect the antiangiogenic effect of therapy with bevacizumab (21).”
BackgroundNeuroEVs: Characterizing Extracellular Vesicles Generated in the Neural Domain
Fowler, C. D. (2019) · The Journal of Neuroscience · doi:10.1523/jneurosci.0146-18.2019 · Cited by 35
Cancer Extracellular Vesicles: Next-Generation Diagnostic and Drug Delivery Nanotools
Palazzolo, S., Memeo, L., Hadla, M., Duzagac, F., Steffan, A., Perin, T., Canzonieri, V., Tuccinardi, T., Caligiuri, I., & Rizzolio, F. (2020) · Cancers · doi:10.3390/cancers12113165 · Cited by 34
Ghosh, S., & Ghosh, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.878058 · Cited by 13
Metadata
- Authors
- Akers, J. C., Ramakrishnan, V., Kim, R., Skog, J., Nakano, I., Pingle, S., Kalinina, J., Hua, W., Kesari, S., Mao, Y., Breakefield, X. O., Hochberg, F. H., Van Meir, E. G., Carter, B. S., & Chen, C. C.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-10-21
- Volume
- 8
- Issue
- 10
- Pages
- e78115
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2150309717
- Cited by
- 337
- References
- 76
- FWCI
- 9.14
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.